Myasthenia gravis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

  NCT06055959· UCB Biopharma SRL· Source

• A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  NCT04951622· Janssen Research & Development, LLC· Source

• A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

  NCT05265273· Janssen Research & Development, LLC· Source

• Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

  NCT07217587· Janssen Research & Development, LLC· Source

• Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

  NCT07246564· UCB Biopharma SRL· Source

• Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis

  NCT06707727· First Affiliated Hospital of Chongqing Medical University· Source

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

  NCT05070858· Regeneron Pharmaceuticals· Source

• A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

  NCT06149559· UCB Biopharma SRL· Source

• An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

  NCT06540144· UCB Biopharma SRL· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 9
• Gene Expression Profiling 5
• Sequence Analysis, RNA 3
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 6
• Flow Cytometry 4
• Immunohistochemistry 1
• Magnetic Resonance Imaging 10
• Machine Learning 8
• Cohort Studies 37
• Genome-Wide Association Study 10

See which targets of this disease your abstract mentions, and go to the people working on them.